142 related articles for article (PubMed ID: 11728835)
21. Lowest effective dose of depot neuroleptics.
Hoencamp E; Haffmans PJ; Jansen GS
Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
[No Abstract] [Full Text] [Related]
22. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
[TBL] [Abstract][Full Text] [Related]
23. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
Glazer WM; Friedhoff LT; Marder SR; Brown WA
Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
[TBL] [Abstract][Full Text] [Related]
24. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
25. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
26. Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.
Chang SS; Javaid JI; Dysken MW; Casper RC; Janicak PG; Davis JM
Psychopharmacology (Berl); 1985; 87(1):55-8. PubMed ID: 3933037
[TBL] [Abstract][Full Text] [Related]
27. Acute dystonia during fixed-dose neuroleptic treatment.
Singh H; Levinson DF; Simpson GM; Lo ES; Friedman E
J Clin Psychopharmacol; 1990 Dec; 10(6):389-96. PubMed ID: 2286708
[TBL] [Abstract][Full Text] [Related]
28. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
Kong DS; Yeo SH
Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
[TBL] [Abstract][Full Text] [Related]
30. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration.
Simpson GM; Yadalam KG; Levinson DF; Stephanos MJ; Lo ES; Cooper TB
J Clin Psychopharmacol; 1990 Dec; 10(6):417-21. PubMed ID: 2286711
[TBL] [Abstract][Full Text] [Related]
31. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities.
Asarnow RF; Marder SR; Mintz J; Van Putten T; Zimmerman KE
Arch Gen Psychiatry; 1988 Sep; 45(9):822-6. PubMed ID: 3046554
[TBL] [Abstract][Full Text] [Related]
32. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
Norman TR; Marriott PF; Kimber NM; Burrows GD
Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
[TBL] [Abstract][Full Text] [Related]
33. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
34. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
[TBL] [Abstract][Full Text] [Related]
35. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
36. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
[TBL] [Abstract][Full Text] [Related]
38. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
[TBL] [Abstract][Full Text] [Related]
40. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Landmark J; Merskey H; Cernovsky ZZ
Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
